Diosmin 520-27-4

Diosmin, as a core ingredient in the treatment of venous diseases, its clinical efficacy highly depends on the precision and stability of the production process. This article focuses on the advanced manufacturing technologies for Diosmin, explaining how process innovations achieve high purity and high bioavailability, ensuring pharmaceutical-grade quality.

Raw Material Selection and Pretreatment
Specific citrus varieties (such as bitter orange and lemon) are used as raw materials. After washing and drying, the fruit peels are crushed to 80 mesh, ensuring efficient release of the Diosmin precursor, Hesperidin.

Directed Hydrolysis Technology
A controlled alkaline hydrolysis reaction is carried out at precise temperatures (60-80°C), converting Hesperidin into Diosmin with a conversion rate greater than 92%. The use of continuous-flow reactors avoids the efficiency bottlenecks and impurity accumulation typical of traditional batch production.

Multistage Purification Process

Supercritical CO₂ Extraction: Removes lipophilic impurities while retaining active flavonoid compounds.

Nanomembrane Filtration: Retains ineffective components with a molecular weight greater than 500 Da, enhancing purity to ≥95%.

Dynamic Crystallization: Controls the crystalline form and particle size to ensure that the dissolution rate of Diosmin for varicose veins treatment meets standards.

Micronization Technology Breakthrough
Airflow pulverization and ball milling are combined to stabilize the particle size of the raw material between 10-50μm, boosting the bioavailability of Diosmin by 40% and significantly enhancing its clinical effectiveness in treating conditions like hemorrhoids.

Green Manufacturing Process
Solvent recovery rate reaches 98%, complying with EHS (Environment, Health, Safety) standards. Enzyme-assisted extraction reduces alkali consumption, cutting wastewater COD values by over 30%.

Digital Quality Control Throughout the Process
Using PAT (Process Analytical Technology), key parameters such as pH, temperature, and purity are monitored in real-time to ensure that each batch meets USP/EP pharmacopoeia standards. Heavy metal residue is kept below 1 ppm, and microbial limits are lower than pharmacopoeia requirements.

Empowering Dosage Form Innovations

Immediate-Release and Sustained-Release Biphase Formulation
By utilizing microencapsulation technology, 12-hour sustained-release granules are developed, maintaining stable blood concentration of Diosmin for chronic venous insufficiency.

Transdermal Delivery System
Through liposome drug delivery technology, Diosmin is combined with topical gels targeting subcutaneous veins, reducing gastrointestinal irritation from oral administration and expanding Diosmin's application scenarios.

We offer:

Customized Process Development: Support for adjusting the Diosmin vs Hesperidin (90:10) ratio.

Technical Documentation Package: Includes process validation, stability studies, and bioequivalence data, accelerating the client’s drug application process.

CDMO Services: Providing integrated production from raw materials to dosage forms, in compliance with GMP standards.